文献速递流行病学与生物统计临床试验与 GCP

降压治疗与不良事件关联的系统综述与荟萃分析

Association between antihypertensive treatment and adverse events: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2021-02-10

结果显示降压治疗与跌倒无显著关联,但增加急性肾损伤、高钾血症、低血压和晕厥风险,同时降低全因死亡、心血管死亡和卒中风险。

要点

  • 降压治疗不增加跌倒风险(汇总风险比1.05,95%CI 0.89-1.24)。
  • 降压治疗增加急性肾损伤、高钾血症、低血压和晕厥风险。
  • 降压治疗降低全因死亡、心血管死亡和卒中风险,但不降低心肌梗死风险。

核心结论

  • 降压治疗与跌倒无证据关联,但与轻度(高钾血症、低血压)和严重不良事件(急性肾损伤、晕厥)存在关联。

研究设计与样本

  • 系统综述与荟萃分析,检索Embase、Medline、CENTRAL和Science Citation Index数据库至2020年4月14日。
  • 纳入标准为成人降压治疗对比安慰剂或无治疗、更多降压药对比更少降压药、或更高血压目标对比更低目标,且随访至少650患者年。

主要发现

  • 7项试验报告跌倒数据,汇总风险比1.05(95%CI 0.89-1.24,τ2=0.009),无证据表明与降压治疗相关。
  • 降压治疗与急性肾损伤风险增加相关(风险比1.18,95%CI 1.01-1.39,τ2=0.037,n=15)。
  • 降压治疗与高钾血症风险增加相关(风险比1.89,95%CI 1.56-2.30,τ2=0.122,n=26)。
  • 降压治疗与低血压风险增加相关(风险比1.97,95%CI 1.67-2.32,τ2=0.132,n=35)。
  • 降压治疗与晕厥风险增加相关(风险比1.28,95%CI 1.03-1.59,τ2=0.050,n=16)。

关键数值与推荐

  • 主要结局为试验随访期间的跌倒,次要结局包括急性肾损伤、骨折、痛风、高钾血症、低钾血症、低血压和晕厥。
  • 额外提取死亡和主要心血管事件相关结局。
  • 使用Cochrane偏倚风险工具评估偏倚风险,采用随机效应荟萃分析合并率比、比值比和风险比。

临床怎么用

  • 数据可用于医生与患者关于启动和继续降压治疗的共享决策。
  • 尤其适用于因既往不良事件或肾功能不佳而处于高伤害风险的患者。

局限性

  • 评估急性肾损伤和高钾血症事件的研究间异质性在聚焦影响肾素-血管紧张素-醛固酮系统的药物时降低。
  • 结果对聚焦导致试验退出的不良事件的敏感性分析稳健。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association between antihypertensive treatment and specific adverse events. DESIGN: Systematic review and meta-analysis. ELIGIBILITY CRITERIA: Randomised controlled trials of adults receiving antihypertensives compared with placebo or no treatment, more antihypertensive drugs compared with fewer antihypertensive drugs, or higher blood pressure targets compared with lower targets. To avoid small early phase trials, studies were required to have at least 650 patient years of follow-up. INFORMATION SOURCES: Searches were conducted in Embase, Medline, CENTRAL, and the Science Citation Index databases from inception until 14 April 2020. MAIN OUTCOME MEASURES: The primary outcome was falls during trial follow-up. Secondary outcomes were acute kidney injury, fractures, gout, hyperkalaemia, hypokalaemia, hypotension, and syncope. Additional outcomes related to death and major cardiovascular events were extracted. Risk of bias was assessed using the Cochrane risk of bias tool, and random effects meta-analysis was used to pool rate ratios, odds ratios, and hazard ratios across studies, allowing for between study heterogeneity (τ2). RESULTS: Of 15 023 articles screened for inclusion, 58 randomised controlled trials were identified, including 280 638 participants followed up for a median of 3 (interquartile range 2-4) years. Most of the trials (n=40, 69%) had a low risk of bias. Among seven trials reporting data for falls, no evidence was found of an association with antihypertensive treatment (summary risk ratio 1.05, 95% confidence interval 0.89 to 1.24, τ2=0.009). Antihypertensives were associated with an increased risk of acute kidney injury (1.18, 95% confidence interval 1.01 to 1.39, τ2=0.037, n=15), hyperkalaemia (1.89, 1.56 to 2.30, τ2=0.122, n=26), hypotension (1.97, 1.67 to 2.32, τ2=0.132, n=35), and syncope (1.28, 1.03 to 1.59, τ2=0.050, n=16). The heterogeneity between studies assessing acute kidney injury and hyperkalaemia events was reduced when focusing on drugs that affect the renin angiotensin-aldosterone system. Results were robust to sensitivity analyses focusing on adverse events leading to withdrawal from each trial. Antihypertensive treatment was associated with a reduced risk of all cause mortality, cardiovascular death, and stroke, but not of myocardial infarction. CONCLUSIONS: This meta-analysis found no evidence to suggest that antihypertensive treatment is associated with falls but found evidence of an association with mild (hyperkalaemia, hypotension) and severe adverse events (acute kidney injury, syncope). These data could be used to inform shared decision making between doctors and patients about initiation and continuation of antihypertensive treatment, especially in patients at high risk of harm because of previous adverse events or poor renal function. REGISTRATION: PROSPERO CRD42018116860.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Albasri A, Hattle M, Koshiaris C, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ. 2021. PMID: 33568342. doi:10.1136/bmj.n189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。